Individualized Molecular Profiling for Allocation to Clinical Trials (IMPACT) Project

Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer

NCT04833205 ·Status: UNKNOWN ·Phase: PHASE2

Evaluation in Real World of Molecular Testing and Treatment Patterns for EGFR Mutation in Lung Cancer Patients

NCT03721289 ·Status: COMPLETED

Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer

NCT03607188 ·Status: COMPLETED ·Phase: PHASE1

Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC)

NCT02995187 ·Status: UNKNOWN ·Phase: PHASE2

A Study to Predict Gefitinib' s Efficacy for Lung Cancer by Plasma Free Nucleic Acids EGFR Gene Mutation Test

NCT02738684 ·Status: UNKNOWN

A Retrospective Molecular Epidemiology Study in Singapore Patients With Advanced Non Small Cell Lung Cancer (NSCLC) of Adenocarcinoma Histology to Assess Epidermal Growth Factor Receptor (EGFR) Mutation Status

NCT01100827 ·Status: UNKNOWN

Study to Evaluate D-1553 in Subjects With Lung Cancer

NCT05383898 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC

NCT04087473 ·Status: COMPLETED

Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis

NCT04148898 ·Status: UNKNOWN ·Phase: PHASE2

Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer

NCT01998126 ·Status: COMPLETED ·Phase: PHASE1

Detection of EGFR Mutations in the Blood of Patients With Non-small Cell Lung Cancer: a Feasibility Study

NCT00717002 ·Status: COMPLETED

Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung Cancer

NCT03346811 ·Status: UNKNOWN ·Phase: PHASE2

Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles

NCT05810350 ·Status: UNKNOWN ·Phase: PHASE2

Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis

NCT01776684 ·Status: UNKNOWN ·Phase: NA

Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation

NCT01204307 ·Status: COMPLETED ·Phase: PHASE2

A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma

NCT04533321 ·Status: UNKNOWN ·Phase: PHASE2

Comparing Efficacy Between Anti-microtubule and Non-anti-microtubule as 3th Therapy After 2nd Line EGFR-TKI Therapy

NCT00836160 ·Status: COMPLETED

High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC

NCT02960607 ·Status: UNKNOWN ·Phase: PHASE2

Diagnosis and Treatment Strategies in Patients With NSCLC With or Without EGFR Mutations.

NCT01525199 ·Status: COMPLETED

Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303）

NCT02388919 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients

NCT04912687 ·Status: COMPLETED ·Phase: NA

Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis

NCT07348965 ·Status: RECRUITING ·Phase: NA

A Phase II Study to Evaluate the Efficacy and Safety of TLC388 in Advanced/Metastatic RCC Patients

NCT01831973 ·Status: COMPLETED ·Phase: PHASE2

Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung Adenocarcinoma

NCT02518802 ·Status: UNKNOWN ·Phase: PHASE3

Nimotuzumab Plus Docetaxel in Chemotherapy-Refractory/Resistant Patients With Advanced Non-Small-Cell Lung Cancer

NCT00983047 ·Status: TERMINATED ·Phase: PHASE2